Srikanth Nagalla, MD
Advertisement
Articles by Srikanth Nagalla, MD
Srikanth Nagalla, MD, discusses the utility of direct oral anticoagulants in cancer-associated thrombosis.
Srikanth Nagalla, MD, discusses research efforts dedicated to the development of timely assays for direct oral anticoagulants in myeloproliferative neoplasms.
Srikanth Nagalla, MD, discusses aspirin recommendations for patients with myeloproliferative neoplasms who are receiving direct oral anticoagulants.
Srikanth Nagalla, MD, discusses the challenges of managing thrombocytopenia in patients with myeloproliferative neoplasms.
Srikanth Nagalla, MD, discusses the utility of direct oral anticoagulants in patients with a myeloproliferative neoplasm–associated venous thromboembolism.
Advertisement
Latest Updated Articles
Dr. Nagalla on the Utility of DOACs in MPN-Associated ThrombosisPublished: January 22nd 2020 | Updated:
Dr. Nagalla on the Challenges of Managing Thrombocytopenia in MPNsPublished: March 16th 2020 | Updated:
Dr. Nagalla on Aspirin Use During DOAC Treatment for MPNsPublished: March 26th 2020 | Updated:
Dr. Nagalla on Need for Timely Assays for DOACs in MPNsPublished: March 27th 2020 | Updated:
Dr. Nagalla on the Utility of DOACs in Cancer-Associated ThrombosisPublished: April 18th 2020 | Updated:
Dr. Nagalla on Efforts to Predict Risk of Thrombosis in Patients With MPNsPublished: April 25th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
3
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
4
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
5